Systemic treatment with the EGFR-MMP-MP1 fusion significantly reduced tumor size in MDA-MB-468 xenograft models, confirming in vivo efficacy against cancer cells and acceptable systemic toxicity. This evidence concerns the gene EGFR and cancer.